## **Supporting Information**

## Ahmadiyeh et al. 10.1073/pnas.0910668107

## **SI Methods**

**Gene Expression in Normal Prostate Tissue.** Gene expression of transcript at chr8: 128,168,145–128,168,232 in 105 normal prostate tissue from men of European-American ancestry (Fig. S1) was determined using the Quantitative Gene Expression application of the Sequenom platform. Briefly, this is a competitive PCR strategy where primers are designed to amplify cDNA in a region of interest, in the presence of differing amounts of

1. Pomerantz MM, et al. (2009) Evaluation of the 8q24 prostate cancer risk locus and MYC expression. *Cancer Res* 69:5568–5574.

competitor oligonucleotide. The competitor sequence differs from the expected amplicon by a single base. The assay uses this single base difference to determine the quantity of each product (cDNA or competitor oligonucleotide) and calculates an  $EC_{50}$  the concentration at which the two products are equal. Further details on the gene-expression assay and statistical analysis used can be found at Pomerantz et al. (1).





**Fig. S1.** Box-plots demonstrating the lack of association between the total number of prostate cancer risk alleles an individual possesses at 8q24 and the expression of a transcript at chr8: 128,168,145–128,168,232 in 105 normal prostate tissue from men of European-American ancestry. The number of 8q24 risk alleles is shown on the *x* axis and normalized gene expression ( $EC_{50}$ ) on the *y* axis. When broken down by number of risk alleles within each risk region, there was still no significant association found.



**Fig. S2.** Normalized 3C interaction frequency of prostate cancer region 3 (red lines) and region 1 (gray lines) in a prostate cancer cell line (LNCaP). *x* axis: genomic position of target fragments (not drawn to scale); 3C interaction frequency ( $\pm$ 1 SEM) of the constant fragment with each of the target fragments including *MYC*, normalized to a 3C interaction within a housekeeping gene, FAM32A. Hatched lines denote position of respective constant fragments (color-coded).



**Fig. S3.** Normalized 3C interaction frequency of the prostate cancer risk regions 1 (Reg1) and 2 (Reg2), and the breast cancer risk region (BrCa) in a fibroblast cell line (LL24). The interaction frequency of shared prostate cancer and colon cancer risk region 3 in fibroblast line LL24, showing no interaction with *MYC*, as previously reported (1). *x* axis: genomic position; *y* axis: 3C interaction frequency (±1 SEM) normalized to a housekeeping gene, FAM32A, demonstrating no interaction of risk regions with *MYC* in fibroblast cell line LL24.

1. Pomerantz MM, et al. (2009) The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41:882–884.



**Fig. S4.** Normalized 3C interaction frequency of the breast cancer risk locus with *MYC* in a normal breast epithelial line, MCF10A, normalized to a house-keeping gene FAM32A. x-axis, genomic position in kb (not drawn to scale); y-axis, 3C interaction frequency, ±1 SEM.



